Last Updated：2025/11/28
In the clinical study, lidanserin showed potent antagonism at 5-HT2A and α1-adrenergic receptors but was never marketed as an antihypertensive.
See correct answer
In the clinical study, lidanserin showed potent antagonism at 5-HT2A and α1-adrenergic receptors but was never marketed as an antihypertensive.
音声機能が動作しない場合はこちらをご確認ください
Edit Histories（0）
